Tomaralimab (Opsona Therapeutics)

托拉利单抗

Report date: 2024/02/06 20:00:33

Base Information

Drug NameTomaralimab (Opsona Therapeutics)
Drug Alias NameOPN-305NM-101NM101
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionToll like receptor 2 antagonists
TargetsToll like receptor 2
Therapy Area/IndicationsDelayed Graft FunctionMyelodysplastic SyndromesNeuralgia +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumUnited States +[12] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesOpsona Therapeutics LtdNeuramedy Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNeuramedy Co Ltd
Inactive CompaniesOpsona Therapeutics Ltd
Active IndicationsParkinson Disease
Inactive IndicationsDelayed Graft FunctionMyelodysplastic SyndromesNeuralgia +[4] 

Other Information

ATC CodeN/A
Related LinksN/A